{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035304","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.083568+00:00","generated_at":"2026-05-30T00:29:50.493345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avenue Therapeutics Q3 2024 net loss $3.1M; cash $2.6M; AJ201 data expected year-end","bullets":["Net loss of $3.1M ($1.92/share) vs net income of $0.5M in Q3 2023.","Cash and equivalents $2.6M at Sep 30, 2024, down $2.3M from Q2 2024.","R&D expenses $2.3M, up from $0.9M in prior year; G&A $0.8M down from $1.2M.","Topline data from AJ201 Phase 1b/2a trial in SBMA expected around year-end 2024.","IV Tramadol Phase 3 safety protocol finalized with FDA; study start subject to financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035304","json":"https://secwatch.observer/filing/0001437749-24-035304.json","markdown":"https://secwatch.observer/filing/0001437749-24-035304.md","text":"https://secwatch.observer/filing/0001437749-24-035304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/0001437749-24-035304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924035304/atxi20241114_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:29:50.493345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}